Self-Assessment Study Program SASP (2020)

The SASP is the AUA’s most popular study tool for exam preparation!

For over 40 years, the AUA's Self-Assessment Study Program (SASP) has been a leading educational resource for urologists-in-training and practicing urologists. Developed each year, the SASP is a 150-question, multiple-choice practice examination that addresses the core curriculum of medical knowledge and latest advances in patient care. The SASP may be taken open or closed book, and provides correct answers with detailed answer rationales, and scientific references.

Why is the SASP the AUA's most popular study tool for exam preparation?

Constructed in the same style as the AUA and ABU's multiple-choice examinations—and offered in three convenient formats to meet your unique study preference—SASP is the AUA's most popular study tool for exam preparation. SASP provides participants their scores, the average scores of their peers, and access to answer commentary and scientific references, allowing participants to evaluate their strengths and weaknesses in various clinical areas and enrich their learning experience. Also, it is important to note that over 30% of the content of the ABU Life Long Learning Knowledge Assessment comes directly from SASP!

The SASP offers up to 20 AMA PRA Category 1 Credits™.


Online 5-Year Bundle (2016-2020)$515$670

Access to the Online, Online Bundle (including prior years) and Q-Stream will begin January 2020. Booklet orders will ship in January.

Due to the impact of COVID-19, our ability to fulfill SASP Booklet orders may be affected. Know that we will work to complete your order as soon as possible. We thank you for your patience and look forward to continuing to serve you. 
Online and Qstream orders will not be affected and access will begin following payment.



Target Audience

  • Urologists
  • Residents
  • Board Candidates
  • Advanced Practice Providers
  • Physician Assistants

Learning Objectives

After completing this activity, learners will be able to: 

  1. Assess their knowledge of urology.
  2. Demonstrate an increased knowledge base of urology.
  3. Apply increased knowledge to improve the quality of patient care.
  4. Evaluate strengths and weaknesses in urology upon review of their personalized participant profile.
  5. Develop a personalized study program to improve their foundation of knowledge.
  6. Discuss core knowledge of urology necessary for the ABU's Qualifying and Life Long Learning Examinations.
Course summary
Course opens: 
Course expires: 

ABU Examination Committee

Stephen A. Boorjian, MD  Carl Rosen Professor in Urology, Vice Chair of Research, Department of Urology, Director, Urologic Oncology Fellowship, Mayo Clinic.  SUO-CTC Organized Clinical Trial Sponsored by FKD (Scientific Study or Trial); Ferring (Consultant or Advisor).

Robert E. Brannigan, MD  Professor, Department of Urology, Chief, Division of Reproductive Surgery and Men’s Health,  Director, Andrology Fellowship,  Northwestern University, Feinberg School of Medicine.  

Mark P. Cain, MD  Professor of Urology, University of Washington, Co-Chief of Pediatric Urology, Seattle Children's Hospital, Chief of Regional Surgical Services, Seattle Children's Hospital. No Disclosures.

Anthony A. Caldamone, MD  Professor of Surgery (Urology) and Pediatrics, The Warren Alpert School of Medicine of Brown University, Head Section of Pediatric Urology, Hasbro Children’s Hospital.  No Disclosures. 

Sam S. Chang, MD, MBA  Patricia and Rodes Hart Endowed Chair in Urologic Surgery, Professor of Urologic Surgery and Oncology, Vanderbilt University Medical Center. Astellas, GLG, Janssen, Want, BMS, Pfizer, Urovant, Urogen (Consultant or Advisor); NIH (Scientific Study or Trial).

Donna M. Connelly  ABU. No Disclosures.

Scott E. Eggener, MD  Professor of Surgery (Urologic Oncology), University of Chicago Medicine. Genomic Health, MDx Health, Opko Health (Scientific Study or Trial); Profound Medical, Sophiris, Insightec (Consultant or Advisor); Janssen (Meeting Participant or Lecturer, Scientific Study or Trial).

Sean P. Elliott, MD, MS  Professor and Vice Chairman, Department of Urology and Director of Reconstructive Urology, University of Minnesota. Boston Scientific (Consultant or Advisor); Urotronic (Consultant or Advisor, Scientific Study or Trial); PercuVision (Investment Interest).

Shelby Englert  AUA. No Disclosures.

David A. Ginsberg, MD  Professor of Clinical Urology, USC Institute of Urology. Procept, Bioness (Scientific Study or Trial); Avadel (Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer). 

Alexander Gomelsky, MD  BE Trichel Professor and Chairman, Department of Urology, Louisiana State University Health Shreveport,  Director of Female Urology, Neurourology, and Reconstructive Pelvic Surgery, Urology Residency Program Director.  No Disclosures.

Christopher M. Gonzalez, MD, MBA  Albert J Jr. and Claire R Speh Professor and Chairman, Department of Urology, Loyola University Medical Center. Aurasense (Investment Interest); AMS, Boston (Other).

C.D. Anthony Herndon, MD  Professor of Surgery (Urology), Chief Pediatric Urology, Virginia Commonwealth University, Co-Surgeon-in-Chief, Children’s Hospital of Richmond. No Disclosures.

James Hu, MD, MPH  Ronald P. Lynch Professor of Urologic Oncology, Director of the LeFrak Center for Robotic Surgery, Weill Cornell Medicine, New York Presbyterian/Weill Cornell.  No Disclosures.

Patrick Kerley  AUA. No Disclosures.

Andrew T. Jones, PhD  Psychometrician, American Board of Surgery. No Disclosures.

H. Henry Lai, MD  Associate Professor of Surgery (Urology) and Anesthesiology, Director of Research, Division of Urologic Surgery, Washington University School of Medicine.  Medtronic, National Institutes of Health, Allergan (Scientific Study or Trial); Teva, Aquinox (Consultant or Advisor).

Maxwell V. Meng, MD  Professor and Chief of Urologic Oncology, Department of Urology, University of California San Francisco. Bristol Myers Squibb (Consultant or Advisor).

Rosalia Misseri, MD  Professor of Urology, Department of Urology, Indiana University School of Medicine, Pediatric Urology Fellowship Director, Riley Hospital for Children at IU Health. No Disclosures. 

Victor Nitti, MD  Chair, AUA Office of Education, Professor of Urology and Obstetrics & Gynecology, Shlomo Raz Chair in Urology, Chief, Female Pelvic Medicine and Reconstructive Surgery, David Geffen School of Medicine at UCLA.  Astellas, Allergan (Health Publishing, Scientific Study or Trial); Serenity Pharmaceuticals (Investment Interest); Medtronic, Amphora (Scientific Study or Trial).

Leslie Rickey, MD, MPH   Associate Professor, Departments of Urology and Obstetrics, Gynecology & Reproductive Sciences, Fellowship Director, Female Pelvic Medicine and Reconstructive Surgery, Yale School of Medicine.  Armada Health, Renovia (Consultant or Advisor).

Hossein Sadeghi-Nejad, MD  Professor of Urology, Division of Urology, Rutgers New Jersey Medical School and Hackensack University Medical Center, Hackensack, NJ, Chief of Urology, VA NJ Health Care System. No Disclosures. 

John D. Seigne, MD Associate Professor of Urology, Chief Section of Urology, Geisel School of Medicine, Dartmouth. Johnson & Johnson (Investment Interest).

Ojas Shah, MD  George F. Cahill Professor of Urology, Director, Division of Endourology and Stone Disease, Director, Endourology Fellowship; Department of Urology, Columbia University College of Physicians and Surgeons.  Boston Scientific (Consultant or Advisor, Meeting Participant or Lecturer); Applaud Medical, Intuitive Surgical (Consultant or Advisor); Coloplast (Meeting Participant or Lecturer); Bristol Myers Squibb, NJ Kidney Stone Center, Novartis (Investment Interest). 

Aseem R. Shukla, MD  Endowed Chair and Director of Minimally Invasive Surgery, Division of Urology, Children’s Hospital of Philadelphia.  Associate Professor of Urology, Perelman School of Medicine at the University of Pennsylvania.  No Disclosures.

Jessica Siculietano  AUA.  No Disclosures.  

Stacy T. Tanaka, MD, MS  Professor of Urology and Pediatrics, Medical Director of Pediatric Spina Bifida Program, Vanderbilt University Medical Center. Centers for Disease Control and Prevention (Scientific Study or Trial).  


Please note: CME Credits expire after three years of original release date. Answers must be submitted by the CME credits expiration deadline to receive credit for that year. Refer to CME expiration table below:

 CME Credits Expiration Date
2020 SASPDecember 31, 2022
2019 SASPDecember 31, 2021
2018 SASPDecember 31, 2020
2017 and prior yearsNot eligible for CME credits.

Original Release Date: January 2020  Expiration Date: December 2022


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 20.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Reproduction Permission: The material contained in this examination is protected under U.S. Copyright law. Duplication of any part of this examination by any means including, but not limited to, photographic reproduction is a FEDERAL OFFENSE.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.


Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.


Please login or register to take this course.

Due to the impact of COVID-19, our ability to fulfill SASP Booklet orders may be affected. Know that we will work to complete your order as soon as possible. We thank you for your patience and look forward to continuing to serve you.

Online and Qstream orders will not be affected and access will begin following payment.

Please log in to see your member rate and purchase.